Ozempic alternatives Canada natural: Shortage, evidence and practical options

Introduction: The Canadian context

As GLP‑1s moved from diabetes care into public conversation about weight loss, Canada faced real supply consequences. Health Canada published supply notices and collaborated with Diabetes Canada, provincial authorities and manufacturers to protect access for people with type 2 diabetes. Meanwhile, Statistics Canada and federal surveys show a sharp rise in overweight and obesity: recent Canadian Health Measures Survey results for 2022–2024 indicate roughly two‑thirds of adults are now classified as overweight or living with obesity — a key driver behind rising interest in weight therapies. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html?utm_source=openai))

What happened with Ozempic and other GLP‑1s?

Beginning in 2023, surging demand for semaglutide (Ozempic/Wegovy) and related agents led to intermittent shortages of specific pen strengths in Canada. Health Canada posted supply notices and convened stakeholders; provinces enacted measures to prioritise patients who need these medicines for diabetes. For example, British Columbia introduced limits on dispensing to protect supply for Canadian residents, and Quebec’s RAMQ authorised substitutions in response to interruptions. These steps were aimed at maintaining access for people with type 2 diabetes while manufacturers ramped supply. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html?utm_source=openai))

How effective are prescription GLP‑1 and GIP/GLP‑1 medicines?

Semaglutide and tirzepatide are supported by large phase‑3 randomized trials showing substantial weight reductions when used alongside lifestyle interventions. Tirzepatide (SURMOUNT trials) produced mean weight losses in the double‑digit percentage range for many participants; semaglutide’s STEP trials also showed significant benefits for weight management. These medicines are clinically useful in appropriate patients, but are prescription‑only, can cause gastrointestinal side effects, and involve long‑term management decisions. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?utm_source=openai))

Who should be prioritised for GLP‑1 therapy?

• People with type 2 diabetes and high cardiovascular or renal risk where GLP‑1s are recommended for cardiorenal protection. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter-13-2024-update?utm_source=openai))
• Patients for whom prior lifestyle interventions have not achieved clinical goals and where a prescriber deems medication appropriate.
• Those who can access long‑term follow‑up and can manage side effects and costs.

Natural, evidence‑based alternatives and complements

If GLP‑1s are unavailable, unaffordable, or not a suitable option, consider these evidence‑based strategies which are accessible across Canada (many ship coast‑to‑coast). All should be used with appropriate medical oversight when you are taking glucose‑lowering drugs.

Soluble (viscous) fibre — an affordable, well‑studied tool

High‑quality meta‑analyses show that supplemental soluble/viscous fibre (psyllium, oat β‑glucan, glucomannan) reduces fasting plasma glucose (FPG), HbA1c and postprandial glucose. One systematic review reported reductions in FPG of roughly 0.6–0.9 mmol/L and improvements in insulin resistance metrics in adults with type 2 diabetes. Practical sources: oats, legumes, psyllium husk, and purpose‑formulated soluble‑fibre products. Introduce fibre gradually and maintain hydration. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))

Time‑restricted eating (TRE) and the 4‑4‑12 framework

TRE (a form of intermittent fasting) restricts daily eating to a consistent window and has demonstrated improvements in fasting glucose, insulin, triglycerides and blood pressure in randomized trials and meta‑analyses. Protocols vary; many Canadians find a 10–12 hour eating window feasible while others prefer shorter windows under clinician guidance. The Feel Great 4‑4‑12 approach is a structured TRE framework that pairs timing with balanced meals; clinical studies of TRE support metabolic benefits when combined with healthy food choices. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/bmjmed/5/1/e001071.full.pdf?utm_source=openai))

Follow Canada’s Food Guide — practical food pattern changes

Canada’s Food Guide recommends lots of vegetables and fruit, whole grains, and a variety of protein foods. Shifting plate composition, increasing protein and fibre at meals, and reducing highly processed foods are foundational strategies supported by Canadian dietary guidance. These changes help appetite control and provide nutrient support during weight loss. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))

Move regularly and preserve muscle

Regular aerobic exercise plus resistance training preserves lean mass during calorie restriction and improves insulin sensitivity. Canadian recommendations (150 minutes of moderate–vigorous activity weekly plus strength work twice weekly) are achievable with home or community programs. Heart & Stroke highlights the strong link between physical activity and cardiometabolic health. ([heartandstroke.ca](https://www.heartandstroke.ca/heart-disease/risk-and-prevention/lifestyle-risk-factors?utm_source=openai))

Practical 6‑step plan (Canada‑friendly)

1. Talk to your family doctor or diabetes team before stopping or changing medications — provinces have different formulary rules and substitution policies. ([ramq.gouv.qc.ca](https://www.ramq.gouv.qc.ca/en/media/15786?utm_source=openai))
2. Get baseline measures: weight, waist, fasting glucose and A1C; Diabetes Canada cites FPG ≥7.0 mmol/L for diabetes and defines IFG as 6.1–6.9 mmol/L. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter3?utm_source=openai))
3. Add viscous soluble fibre (oats, psyllium, glucomannan) gradually — a pragmatic supplemental dose may be 5–12 g/day extra, depending on product and tolerance. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
4. Try a consistent TRE eating window (e.g., 10–12 hours) and adapt to work, family and Canadian seasons; the 4‑4‑12 is one clinician‑guided model. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/bmjmed/5/1/e001071.full.pdf?utm_source=openai))
5. Follow Canada’s Food Guide for plate composition and increase daily movement. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))
6. Use evidence‑based supportive products (e.g., a soluble‑fibre matrix, yerba‑mate extract) only after checking Health Canada labeling / NPN status and discussing with your clinician — these are adjuncts, not replacements for medical care. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))

How Feel Great may support Canadians (balance + Unimate + 4‑4‑12)

The Feel Great system is a lifestyle support toolkit: Balance is a soluble‑fibre matrix designed to help moderate post‑meal glucose excursions; Unimate is a yerba‑mate extract with chlorogenic acids to support alertness and energy in short‑term studies; and the 4‑4‑12 TRE protocol provides a consistent eating schedule. When used alongside whole‑food eating (Canada’s Food Guide), exercise and medical oversight, these elements may help individuals manage appetite and post‑meal glucose rises. They are not medications and should be used as part of a comprehensive plan agreed with your healthcare team. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))

FAQ

1. Q: How are diabetes and prediabetes defined in Canada?
   A: Diabetes Canada uses fasting plasma glucose (FPG) ≥7.0 mmol/L for diabetes; impaired fasting glucose (IFG) is defined as FPG 6.1–6.9 mmol/L, and A1C 6.0–6.4% is considered prediabetes in their guidance. Discuss individual interpretation with your clinician. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter3?utm_source=openai))
2. Q: What blood sugar targets should I aim for?
   A: For many adults with type 2 diabetes, Diabetes Canada suggests fasting/preprandial targets ~4.0–7.0 mmol/L and 2‑hour postprandial targets of 5.0–10.0 mmol/L, depending on individual factors. ([diabetes.ca](https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-8?utm_source=openai))
3. Q: Do provincial drug plans cover semaglutide/tirzepatide for weight?
   A: Coverage varies by province and indication (diabetes vs obesity). Many public plans prioritise treatment for diabetes or specific criteria; check your provincial formulary or RAMQ in Quebec. ([ramq.gouv.qc.ca](https://www.ramq.gouv.qc.ca/en/media/15786?utm_source=openai))
4. Q: What dose of viscous fibre is effective?
   A: Clinical studies use variable doses; meta‑analyses suggest measurable effects with added viscous fibre in the ~5–12 g/day range depending on type (psyllium, β‑glucan, glucomannan). Start low and increase slowly to reduce GI side effects. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
5. Q: Is TRE safe if I take glucose‑lowering medication?
   A: TRE can change glucose patterns and may increase hypoglycaemia risk if you take insulin or insulin secretagogues. Do TRE only under clinician guidance with appropriate monitoring. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/bmjmed/5/1/e001071.full.pdf?utm_source=openai))

References & scientific sources

• Health Canada — Supply of Ozempic and other GLP‑1 receptor agonists: notice and updates. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html?utm_source=openai))
• Diabetes Canada — Clinical Practice Guidelines and statements on GLP‑1 supply. ([diabetes.ca](https://www.diabetes.ca/media-room/news/response-to-the-anticipated-ozempic-supply-disrupt?form=donate&s_appealCode=1058-350%3A+11984+%2F+30110+%2F+DM-NAT+ONLINE+Landing+Page+2025+%2F+Online+donation&utm_source=openai))
• Statistics Canada — Canadian Health Measures Survey, prevalence of overweight and obesity, 2022–2024. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/daily-quotidien/251002/dq251002b-eng.htm?HPA=1&utm_source=openai))
• Canadian Institute for Health Information (CIHI) — Ozempic the leading medication driving growth in public drug spending. ([cihi.ca](https://www.cihi.ca/en/news/ozempic-the-leading-medication-driving-growth-in-public-drug-spending-in-canada?utm_source=openai))
• NEJM — Tirzepatide (SURMOUNT) trials for obesity. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?utm_source=openai))
• PubMed / systematic review — Soluble fibre supplementation improves glycaemic control. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
• BMJ Medicine — Systematic review and network meta‑analysis on time‑restricted eating and metabolic outcomes. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/bmjmed/5/1/e001071.full.pdf?utm_source=openai))
• Health Canada — Canada’s Food Guide. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))
• Heart & Stroke Foundation — lifestyle risk factors and physical activity guidance. ([heartandstroke.ca](https://www.heartandstroke.ca/heart-disease/risk-and-prevention/lifestyle-risk-factors?utm_source=openai))
• BC Government news release — protecting semaglutide supply. ([news.gov.bc.ca](https://news.gov.bc.ca/releases/2023HLTH0046-000554?utm_source=openai))

Medical disclaimer

This article is informational and written for a Canadian audience. It is not medical advice. Do not stop, start, or change prescription medicines without talking to your healthcare provider. For drug shortage questions and provincial coverage, contact your pharmacist or provincial drug plan. The Feel Great system and any supplements are lifestyle supports and are not medicines; they may help support metabolic patterns but should be used under clinical guidance when you take glucose‑lowering drugs.

Introduction: A Canadian wake‑up call

Shortly after semaglutide (marketed as Ozempic and Wegovy) became widely discussed for weight loss, Canada saw intermittent shortages. Health Canada posted supply notices and worked with provincial authorities to protect people with diabetes who rely on these treatments. Meanwhile, public health data show the scale of the problem: during 2022–2024 more than two‑thirds (≈68%) of Canadian adults aged 18–79 were classified as overweight or living with obesity — a trend that fuels demand for both medical and non‑medical weight solutions. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html?utm_source=openai))

What happened with Ozempic in Canada?

In 2023–2024, global demand for GLP‑1 receptor agonists (including semaglutide/Ozempic) exceeded supply, producing intermittent shortages of certain pen strengths in Canada. Health Canada issued supply notices and collaborated with professional bodies (for example Diabetes Canada) to prioritise supply for people with type 2 diabetes. Provinces took additional steps — B.C. moved to restrict dispensing to protect diabetic patients, and Quebec’s RAMQ authorised substitutions to manage supply locally. These measures helped stabilise access while regulators continued to monitor supply. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html?utm_source=openai))

Why shortages matter in Canada (costs and access)

GLP‑1 and related agents became significant drivers of public drug spending in Canada: CIHI reported that semaglutide (Ozempic/Wegovy) was a leading single‑drug cost driver in recent public drug expenditure data. That combination of high demand, high cost and limited manufacturing capacity explains why provinces and Health Canada had to prioritise distribution. ([cihi.ca](https://www.cihi.ca/en/news/ozempic-the-leading-medication-driving-growth-in-public-drug-spending-in-canada?utm_source=openai))

How effective are GLP‑1 and dual GIP/GLP‑1 drugs?

Large phase‑3 trials show that these medicines can produce substantial average weight reductions when used with lifestyle support. For example, tirzepatide (a dual GIP/GLP‑1 molecule) produced mean weight losses of ~15–20% in SURMOUNT trials in people with obesity, while semaglutide trials (STEP series) demonstrated clinically meaningful weight loss vs placebo. These are prescription therapies with proven efficacy, but they also have known side effects (mostly gastrointestinal) and require medical supervision. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?utm_source=openai))

Who should keep GLP‑1 therapy as first choice?

1. People with type 2 diabetes at high cardiovascular or renal risk where guidelines recommend GLP‑1s for cardiorenal benefit. ([guidelines.diabetes.ca](https://guidelines.diabetes.ca/cpg/chapter-13-2024-update?utm_source=openai))
2. People where prior weight‑management strategies have failed and medication is appropriate under clinical guidance.
3. Those with reliable, ongoing access and ability to manage side effects under medical care.

For others: evidence‑based natural alternatives and complements (what works)

If you cannot access or prefer not to use GLP‑1 medicines, Canada‑relevant, evidence‑based strategies can still produce meaningful metabolic improvements. Below are practical options with research backing:

1) Soluble fibre (viscous fibres like oat β‑glucan, psyllium, glucomannan)

Systematic reviews and meta‑analyses show that adding soluble/viscous fibre lowers fasting plasma glucose and HbA1c, reduces postprandial glucose spikes, and can modestly lower body weight. One meta‑analysis found reductions in fasting plasma glucose by around 0.6–0.9 mmol/L and improvements in HOMA‑IR with soluble fibre supplementation. In practice, a daily target of extra viscous fibre (for example 5–12 g beta‑glucan or psyllium, introduced gradually) can help blunt post‑meal glucose rises. Always check with your pharmacist for interactions and ensure sufficient fluid intake. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))

2) Time‑restricted eating / intermittent fasting (the 4‑4‑12 and other TRE windows)

Time‑restricted eating (TRE) — limiting food to a consistent daily eating window — has improved fasting glucose, insulin sensitivity, triglycerides and systolic blood pressure in randomized trials and meta‑analyses. Protocols vary; the Feel Great 4‑4‑12 (fasting 12 hours overnight, eating within a 12‑hour window, or other clinician‑guided windows) is one structured option. TRE can be adapted to Canadian lifestyles and seasons (shorter daylight in winter may require adjustment). TRE is not suitable for everyone (pregnancy, eating disorders, certain medications) — consult your healthcare provider first. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/bmjmed/5/1/e001071.full.pdf?utm_source=openai))

3) Follow Canada’s Food Guide patterns and protein‑rich meals

Canada’s Food Guide emphasises vegetables and fruit, whole grains, and protein foods (including plant‑based proteins), plus water as the beverage of choice. Practical shifts — increase whole grains, vegetables, legumes, oily fish and higher‑protein breakfasts — help appetite control and metabolic health. Combine these with portion awareness and behavioural strategies for better long‑term weight outcomes. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))

4) Move more, preserve muscle

Regular aerobic and resistance exercise supports weight loss, preserves lean mass during calorie reduction, and improves insulin sensitivity. Heart & Stroke and Canadian guidelines recommend at least 150 minutes of moderate to vigorous aerobic activity per week plus twice‑weekly muscle‑strengthening activities. Even brisk walking and home‑based resistance routines matter. ([heartandstroke.ca](https://www.heartandstroke.ca/heart-disease/risk-and-prevention/lifestyle-risk-factors?utm_source=openai))

5) Sleep, stress, environment and seasonal factors

Sleep shortfalls and chronic stress dysregulate appetite hormones and insulin. In Canada, long winters can lower activity and vitamin D exposure; aim to maintain physical activity when weather limits outdoor time, and discuss vitamin D with your clinician if deficient. These upstream supports amplify dietary and activity benefits. (See provincial resources for local services and coverage.)

Quick comparison: GLP‑1 medicines vs natural/behavioural strategies (evidence snapshot)

Practical plan for Canadians seeking natural Ozempic alternatives

1. Talk with your family doctor, diabetes clinic, or pharmacist before stopping or switching any medicine — provinces differ in formulary rules and substitution policies. ([ramq.gouv.qc.ca](https://www.ramq.gouv.qc.ca/en/media/15786?utm_source=openai))
2. Measure and track key numbers: weight, waist circumference, fasting glucose (target fasting ~4.0–7.0 mmol/L for most people with diabetes per Diabetes Canada), and A1C targets. Diabetes Canada defines IFG/prediabetes thresholds slightly differently from ADA — FPG 6.1–6.9 mmol/L for IFG in their guidance. ([diabetes.ca](https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-8?utm_source=openai))
3. Increase soluble fibre (oats, legumes, psyllium, glucomannan) gradually — aim for extra 5–12 g/day of viscous fibre where tolerated. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
4. Try a consistent time‑restricted eating window (for example 10–12 hours total eating window); the 4‑4‑12 framework is one structured approach — adapt it to work and daylight in your province/season. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/bmjmed/5/1/e001071.full.pdf?utm_source=openai))
5. Prioritise protein at meals, daily vegetables, whole grains and regular physical activity per Canada’s Food Guide. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))
6. Consider evidence‑based supplements/products as supportive tools (e.g., a soluble‑fibre matrix product, or a plant‑based stimulant like yerba‑mate) — check Health Canada NPNs, provincial shipping options and discuss with your healthcare team. (Not a medication; may help manage post‑meal glucose response or energy.) ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))

How Feel Great (Balance, Unimate, 4‑4‑12) may fit — a clinician’s perspective

Feel Great is a lifestyle support system combining a soluble fibre matrix (Balance), a yerba‑mate extract (Unimate) containing chlorogenic acids, and the 4‑4‑12 time‑restricted eating framework. Used as part of a comprehensive plan — along with whole‑food eating in line with Canada’s Food Guide, exercise, sleep and medical follow‑up — these components may help blunt post‑meal glucose and support appetite management. They are not medicines and are intended as adjuncts to lifestyle change. Always check product labelling for a Health Canada NPN where applicable and discuss use with your prescriber, especially if you take glucose‑lowering medications (risk of hypoglycaemia if calorie intake changes). (See references for supporting trials about viscous fibre and TRE.) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))

FAQ

1. Q: What is the difference between Ozempic and Wegovy?
   A: Both contain semaglutide but Wegovy is specifically indicated for chronic weight management at a higher weekly dose; Ozempic is indicated for type 2 diabetes (different dosing and packaging). Discuss with your prescriber which is right based on diagnosis and goals. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK601688/?utm_source=openai))
2. Q: How quickly do natural approaches work?
   A: Soluble fibre can reduce postprandial spikes within days; measurable weight and A1C changes typically take weeks to months depending on adherence and baseline health. TRE and diet changes show metabolic benefits within 4–12 weeks in trials. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
3. Q: Is yerba‑mate safe and effective?
   A: Yerba‑mate contains bioactives (caffeine, chlorogenic acids) that may support alertness and metabolic markers in short‑term studies, but long‑term safety and dosing vary. Look for Health Canada–approved products where applicable and discuss stimulant use if you have cardiovascular disease or take stimulants.
4. Q: What fasting glucose values should I aim for?
   A: For many adults with diabetes, Diabetes Canada cites a fasting/preprandial target of ~4.0–7.0 mmol/L; diagnostic thresholds are FPG ≥7.0 mmol/L for diabetes and IFG 6.1–6.9 mmol/L per Diabetes Canada definitions. Discuss individual targets with your clinician. ([diabetes.ca](https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-8?utm_source=openai))
5. Q: Can children/teens use GLP‑1s or these natural strategies?
   A: Use of GLP‑1s in younger people follows strict clinical criteria and specialist oversight. Lifestyle strategies (balanced food per Canada’s Food Guide, age‑appropriate activity, sleep) are first‑line for youth — consult paediatric care teams. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))

References & scientific sources

• Health Canada — Supply of Ozempic and other GLP‑1 receptor agonists (supply notices). ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ozempic.html?utm_source=openai))
• Diabetes Canada — Clinical Practice Guidelines and response to intermittent shortages. ([diabetes.ca](https://www.diabetes.ca/media-room/news/response-to-the-anticipated-ozempic-supply-disrupt?form=donate&s_appealCode=1058-350%3A+11984+%2F+30110+%2F+DM-NAT+ONLINE+Landing+Page+2025+%2F+Online+donation&utm_source=openai))
• Statistics Canada — Canadian Health Measures Survey results 2022–2024 (overweight/obesity prevalence). ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/daily-quotidien/251002/dq251002b-eng.htm?HPA=1&utm_source=openai))
• Canadian Institute for Health Information (CIHI) — Ozempic as leading medication driving public drug spending. ([cihi.ca](https://www.cihi.ca/en/news/ozempic-the-leading-medication-driving-growth-in-public-drug-spending-in-canada?utm_source=openai))
• British Columbia government news release on protecting semaglutide supply (Adrian Dix). ([news.gov.bc.ca](https://news.gov.bc.ca/releases/2023HLTH0046-000554?utm_source=openai))
• Quebec RAMQ — Notice of alternative medication authorizations during shortages. ([ramq.gouv.qc.ca](https://www.ramq.gouv.qc.ca/en/media/15786?utm_source=openai))
• NEJM — Tirzepatide (SURMOUNT) weight‑loss trials. ([nejm.org](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?utm_source=openai))
• PubMed / systematic review — Soluble fibre reduces fasting glucose and HbA1c (meta‑analysis). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33162192/?utm_source=openai))
• BMJ Medicine — Systematic review & network meta‑analysis on time‑restricted eating and metabolic outcomes. ([bmjmedicine.bmj.com](https://bmjmedicine.bmj.com/content/bmjmed/5/1/e001071.full.pdf?utm_source=openai))
• Health Canada — Canada’s Food Guide and dietary recommendations. ([canada.ca](https://www.canada.ca/en/health-canada/services/food-guide.html?utm_source=openai))

Medical disclaimer

This article is informational and written for Canadians seeking evidence‑based guidance. It is not medical advice. Do not stop, start or change prescription medicines without talking to your healthcare provider. For questions about drug shortages or coverage, contact your provincial drug plan or pharmacist. The Feel Great system and individual products are not medicines; they are lifestyle supports that may help when used with clinical supervision.

Frequently Asked Questions